| Idelalisib and rituximab in relapsed chronic lymphocytic leukemia RR Furman, JP Sharman, SE Coutre, BD Cheson, JM Pagel, P Hillmen, ... New England Journal of Medicine 370 (11), 997-1007, 2014 | 2170 | 2014 |
| Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia JA Burger, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, ... New England Journal of Medicine 373 (25), 2425-2437, 2015 | 1693 | 2015 |
| Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia JC Byrd, B Harrington, S O’Brien, JA Jones, A Schuh, S Devereux, ... New England Journal of Medicine 374 (4), 323-332, 2016 | 991 | 2016 |
| Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up B Eichhorst, T Robak, E Montserrat, P Ghia, CU Niemann, AP Kater, ... Annals of Oncology 32 (1), 23-33, 2021 | 884 | 2021 |
| Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial K Fischer, J Bahlo, AM Fink, V Goede, CD Herling, P Cramer, ... Blood, The Journal of the American Society of Hematology 127 (2), 208-215, 2016 | 795 | 2016 |
| Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia L Granziero, P Ghia, P Circosta, D Gottardi, G Strola, M Geuna, ... Blood, The Journal of the American Society of Hematology 97 (9), 2777-2783, 2001 | 721 | 2001 |
| The microenvironment in mature B-cell malignancies: a target for new treatment strategies JA Burger, P Ghia, A Rosenwald, F Caligaris-Cappio Blood, The Journal of the American Society of Hematology 114 (16), 3367-3375, 2009 | 683 | 2009 |
| Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations K Stamatopoulos, C Belessi, C Moreno, M Boudjograh, G Guida, ... Blood 109 (1), 259-270, 2007 | 664 | 2007 |
| The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee E Campo, ES Jaffe, JR Cook, L Quintanilla-Martinez, SH Swerdlow, ... Blood, The Journal of the American Society of Hematology 140 (11), 1229-1253, 2022 | 644 | 2022 |
| Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia Y Herishanu, I Avivi, A Aharon, G Shefer, S Levi, Y Bronstein, M Morales, ... Blood, The Journal of the American Society of Hematology 137 (23), 3165-3173, 2021 | 607 | 2021 |
| Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase … JP Sharman, M Egyed, W Jurczak, A Skarbnik, JM Pagel, IW Flinn, ... The Lancet 395 (10232), 1278-1291, 2020 | 591 | 2020 |
| Diagnostic criteria for monoclonal B‐cell lymphocytosis GE Marti, AC Rawstron, P Ghia, P Hillmen, RS Houlston, N Kay, ... British journal of haematology 130 (3), 325-332, 2005 | 527 | 2005 |
| Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies A Agathangelidis, N Darzentas, A Hadzidimitriou, X Brochet, F Murray, ... Blood, The Journal of the American Society of Hematology 119 (19), 4467-4475, 2012 | 509 | 2012 |
| International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia AC Rawstron, N Villamor, M Ritgen, S Böttcher, P Ghia, JL Zehnder, ... Leukemia 21 (5), 956-964, 2007 | 486 | 2007 |
| Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study JA Burger, PM Barr, T Robak, C Owen, P Ghia, A Tedeschi, O Bairey, ... Leukemia 34 (3), 787-798, 2020 | 474 | 2020 |
| B-cell clones as early markers for chronic lymphocytic leukemia O Landgren, M Albitar, W Ma, F Abbasi, RB Hayes, P Ghia, GE Marti, ... New England Journal of Medicine 360 (7), 659-667, 2009 | 427 | 2009 |
| Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis F Murray, N Darzentas, A Hadzidimitriou, G Tobin, M Boudjogra, ... Blood, The Journal of the American Society of Hematology 111 (3), 1524-1533, 2008 | 415 | 2008 |
| Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial JC Byrd, P Hillmen, P Ghia, AP Kater, A Chanan-Khan, RR Furman, ... Journal of clinical oncology 39 (31), 3441, 2021 | 387 | 2021 |
| Recurrent mutations refine prognosis in chronic lymphocytic leukemia P Baliakas, A Hadzidimitriou, LA Sutton, D Rossi, E Minga, N Villamor, ... Leukemia 29 (2), 329-336, 2015 | 379 | 2015 |
| Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22 P Ghia, G Strola, L Granziero, M Geuna, G Guida, F Sallusto, N Ruffing, ... European journal of immunology 32 (5), 1403-1413, 2002 | 361 | 2002 |
